Number of Shares
0
Previous 0 NaN%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

BUY
$3.64 - $8.23 $0 - $0
0 New
0 $0
Q2 2024

Jul 23, 2024

BUY
$4.08 - $6.39 $0 - $0
0 New
0 $0
Q1 2024

Apr 30, 2024

BUY
$2.94 - $4.24 $0 - $0
0 New
0 $0
Q4 2023

Feb 07, 2024

BUY
$3.0 - $4.01 $0 - $0
0 New
0 $0
Q3 2023

Oct 30, 2023

BUY
$3.6 - $4.46 $0 - $0
0 New
0 $0
Q3 2023

Oct 25, 2023

BUY
$3.6 - $4.46 $0 - $0
0 New
0 $0
Q2 2023

Aug 10, 2023

BUY
$3.94 - $5.8 $0 - $0
0 New
0 $0
Q1 2023

May 15, 2023

BUY
$3.22 - $4.61 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023

BUY
$2.81 - $4.45 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022

BUY
$2.82 - $7.52 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022

BUY
$2.73 - $5.61 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022

BUY
$3.83 - $6.24 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022

BUY
$4.47 - $5.56 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021

BUY
$4.46 - $7.11 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021

BUY
$6.05 - $10.09 $0 - $0
0 New
0 $0
Q1 2021

May 13, 2021

BUY
$6.84 - $17.58 $0 - $0
0 New
0 $0
Q4 2020

Feb 02, 2021

BUY
$5.0 - $9.15 $0 - $0
0 New
0 $0
Q3 2020

Nov 13, 2020

BUY
$3.96 - $6.15 $0 - $0
0 New
0 $0
Q2 2020

Aug 13, 2020

BUY
$3.08 - $6.56 $0 - $0
0 New
0 $0
Q1 2020

May 13, 2020

BUY
$2.35 - $7.08 $0 - $0
0 New
0 $0
Q4 2019

Feb 14, 2020

BUY
$4.96 - $7.75 $0 - $0
0 New
0 $0
Q3 2019

Nov 13, 2019

BUY
$6.38 - $9.69 $0 - $0
0 New
0 $0
Q2 2019

Aug 13, 2019

BUY
$5.93 - $10.57 $0 - $0
0 New
0 $0
Q1 2019

May 15, 2019

BUY
$6.95 - $13.25 $0 - $0
0 New
0 $0

Others Institutions Holding CRMD

About CorMedix Inc.


  • Ticker CRMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,208,200
  • Market Cap $410M
  • Description
  • CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...
More about CRMD
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.